New Delhi: Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo are working on a three-year plan for exploiting synergies in operations to enhance their generic as well as branded business across the globe.
Ranbaxy CEO and Managing Director Atul Sobti has said
that the three-year plan was aimed at enhancing the value of
both the companies with a focus on branded drugs, its back-end
support, which includes research and development and
marketing.
According to market analysts, there could be four key
areas that the synergy plan between the two companies could
address.
Accessing the Japanese market with Ranbaxy's products
through Daiichi's network to cash in on the government's plan
to double generic market share from the current USD 3.5
billion dollars in the next few years is one of the key areas,
a report by brokerage firm Motilal Oswal said.
The report also said Daiichi can also leverage on
Ranbaxy's distribution network to launch its products, where a
beginning has already been made in Romania and Mexico.
Asked about the time frame for announcing details of the
three-year plan during a conference call for third quarter
results on Monday, Sobti said the company expects it to be
out by December this year.
Bureau Report
First Published: Wednesday, October 28, 2009, 19:00